Keep up to date with technology leadership moves by category.

Sunday, 01 November 2015 10:07

Healthcare Industry – 25 Open CEO Roles and 56 CEO Appointments Featured

Written by
Rate this item
(0 votes)

Compilation of Open CEO Roles and Placements in the Healthcare Industry in the 45 days ended October 26, 2015
PREPARED BY: Vell Executive Search
DATE: September 11 to October 26, 2015

Healthcare Industry - CEOs Wanted 

Bayer AG
Germany
$54.6B
June 2014
Bayer AG CEO Marijn Dekkers will step down at the end of 2016, setting up a contest for the top job at one of Germany’s largest companies.
Haemonetics Corporation
Massachusetts
$899.3M
September 2015
Haemonetics Corporation announced that Brian Concannon has resigned from his role as President and CEO and as a Director to pursue other opportunities. In connection with Mr. Concannon's resignation, Ronald Gelbman, a member of Haemonetics' Board of Directors, has been appointed as Interim CEO.
Aegerion Pharmaceuticals
Massachusetts
$158.4M
July 2015
Marc Beer offered his resignation as CEO and member of the board, as did Craig Fraser as COO. Board member Sandford Drexel Smith has been appointed interim CEO, while the company conducts a search to identify a successor.
Sequenom
California
$145.3M
September 2015
Sequenom appointed Dirk van den Boom, Ph.D. to the position of interim President and CEO. Dr. van den Boom succeeds William J. Welch following his resignation from that role, and as a director, to pursue other interests. In addition, Dr. van den Boom will continue to serve as the company’s Chief Scientific and Strategy Officer.
Analytik Jena AG      
Thuringia         
$139.2M          
October 2015  
Analytik Jena AG announced the departure of Klaus Berka as its CEO, whose contract expires in March 2017. Ulrich Krauss, who has more than two decades of experience in a variety of international management positions at Carl Zeiss, will be taking charge of the newly established Executive Board area of responsibility, Marketing and Sales, on November 1, 2015.
Abano Healthcare Group Limited
New Zealand
$133.2M
September 2015
Alan Clarke has been CEO and Managing Director at Abano Healthcare Limited, a role he has held for 15 years. He announced last year his intention to step down from that role at 2015’s Annual Meeting in November 2015.
ARIAD Pharmaceuticals Massachusetts
$105.4M
April 2015
Harvey J. Berger, 64 will retire from the cancer drug company he founded, when a successor is named or by Dec. 31 at the latest, after reaching a settlement with the Connecticut hedge fund. The board has begun a search for a new CEO.
Sarepta Therapeutics
Massachusetts
$9.8M
March 2015
Sarepta Therapeutics named Edward Kaye, M.D., the company’s Chief Medical Officer (CMO), as interim CEO, replacing Christopher Garabedian.
Allegra Orthopaedics Limited
New South Wales        
$6.57M
September 2015
Allegra Orthopaedics Limited announced that the Company's CEO and CFO, Tom Milicevic, has tendered his resignation that has been agreed will become effective on October 9, 2015. Allegra Orthopaedics proposes to undertake a management restructure that reflects the size of its business and it is envisaged that this change will be effected over the next six months. In the meantime, the CEO's role will be subsumed under the role of Managing Director with Peter Welsh remaining in the expanded role.
Lpath
California
$3.56M
September 2015
Lpath announced that Gary Atkinson has been appointed interim CEO of Lpath. Mr. Atkinson will continue to serve as Lpath's CFO.
LBT Innovations
South Australia
$1.82M            
October 2015
The Board of LBT Innovations Limited has announced that CEO, Lusia Guthrie, will retire from the company as CEO in 2016 due to health reasons. Mrs. Guthrie has been CEO of the technology developer since she co-founded the company in 2004.
Vigmed Holding
Skåne County  
$0.35M            
October 2015
Vigmed Holding AB (publ) announced that the Board of Directors has decided to appoint Henrik Olsen as interim CEO with immediate effect. This means that Finn Ketler will step down from his present position as CEO. Henrik Olsen, 47, has been employed at Vigmed since the autumn 2013, where he has been responsible for Vigmed's initial establishment on overseas markets.
Genkyotex S.A.
Geneva
NA
September 2015
Genkyotex announced that Dr. Ursula M. Ney has resigned as CEO and as a member of the Board. Genkyotex’s Board of Directors has promoted Elias Papatheodorou to the role of acting CEO. Papatheodorou joined Genkyotex in March 2015 as Chief Business Officer.
Upson Regional Medical Center
Georgia           
NA       
September 2015
Upson Regional Medical Center confirmed the resignation of CEO David Castleberry. Mr. Castleberry has given 90 days of notice before his departure to a career advancing opportunity in Savannah.
Stanford Health Care           
California         
NA       
September 2015
Stanford Health Care announced that Amir Dan Rubin, president and CEO, will leave at the end of this year to join UnitedHealth Group and its Optum organization as EVP.
Helix Biopharma
Ontario
NA
September 2015
Helix BioPharma announced that Robert Verhagen has resigned as President and CEO and as a member of the Board of Directors. Verhagen will continue to serve as CEO to assist in the company's management transition and he has been with Helix since 2012. In the event that the Board has not appointed a new CEO by November 1, 2015, Helix's Board of Directors intends to appoint Yvon Bastien, Chairman of the Board, to assume the role of President and CEO on an interim basis.
AcelRx Pharmaceuticals
California
NA
March 2015
Former Gilead Sciences and ALZA exec Howard B. Rosen is the current interim CEO of AcelRx.
Avalanche Biotechnologies
California
NA
July 2015
Thomas W. Chalberg, Jr., Ph.D. has resigned as CEO and president and as a member of the Board. SVP, Business Operations Hans P. Hull will serve as interim CEO and president. Avalanche's Board has appointed independent directors John P. McLaughlin and Paul D. Wachter to a Special Committee to lead the search for a permanent CEO and additional directors.
CorMedix
New Jersey
NA
July 2015
The Board is determined to transition the role of CEO from Randy Milby to an individual with clinical trial management and other management experience that will lead clinical, commercial, and financial oversight and long term vision for CorMedix. The company has begun a search for a CEO with the assistance of an executive search firm.
Carolinas HealthCare System
North Carolina
NA
June 2015
CEO Michael Tarwater announced that he’ll retire next June. The board will hire an executive search firm to help find Tarwater’s replacement.
Salix Pharmaceuticals
North Carolina
NA
January 2015
Salix Pharmaceuticals’ President and CEO Carolyn Logan plans to retire by the end of January, months after an accounting issue may have derailed the drug maker’s takeover. Chairman Tom D’Alonzo will become acting CEO. The company will hire a search firm to look for a CEO.
Titanium Healthcare
Texas
NA
May 2015
CEO James York has been terminated. CFO Chuck Talley and COO Chris Mashburn will share the CEO duties until a new CEO is appointed
Cancer Treatment Centers of America   
Illinois
NA       
October 2015
Cancer Treatment Centers of America announced that Gerard van Grinsven resigned as president and CEO to pursue other interests. The company named COO Steve Mackin and Southeast Regional Medical Center CEO Anne Meisner as interim leaders of the company until a successor is named.
Maxor National Pharmacy Services
Texas  
NA       
October 2015
"Maxor National Pharmacy Services, LLC announced that the company's CEO, John Ward, will retire in 2016. It is expected that the company will select a new CEO by the end of 2016. Ward will remain a member of the Board and retain his significant ownership position in the Company upon his retirement.
Memorial Hermann Healthcare System   
Texas  
NA       
October 2015
As a member of the board, Ward will participate in the process of selecting a new CEO. Maxor has hired Chartwell Partners to conduct a national search for Mr. Ward's successor."

 

Healthcare Industry - CEOs Appointed

UnitedHealth Group Minnesota $138.2B September 2015 David Allazetta is the new president and CEO of UnitedHealthcare in Arizona and New Mexico. He takes the place of Beth Soberg, who had been responsible for Arizona, Colorado, New Mexico and Wyoming. Those markets were split in two, so now Soberg is responsible for Colorado and Wyoming and Allazetta is being brought in from it's Nevada market to run Arizona and New Mexico. As he moves to his new office in downtown Phoenix, Allazetta is flying back and forth between Las Vegas and Phoenix.
Merck
Hessen           
$13.72B          
October 2015  
Stefan Oschmann has been appointed chairman and CEO of Merck KG, effective 29 April 2016. Oschmann had been appointed Merck's deputy CEO at the beginning of 2015. The current chairman and CEO, Karl-Ludwig Kley, will retire after eight years in the post.
Team Health Holdings Tennessee      
$3.22M
October 2015  
AmSurg  announced merger with Team Health Holdings to create the market leader in physician services.Christopher A. Holden will be CEO and will lead a management team comprised of senior leaders from both organizations. The AmSurg and Sheridan operations will retain their brands.
UDG Healthcare
Dublin
$2.381B
September 2015
UDG Healthcare PLC announced the retirement of Liam FitzGerald as Group CEO, effective March 31, 2016. Having been aware over the last number of years of Mr. FitzGerald's early retirement aspirations, the Board has been actively involved in succession planning and has nominated Brendan McAtamney, Group COO since 2013, as his successor.
Nuffield Health          
Surrey 
$1.107B          
October 2015
Nuffield Health has announced the departure of David Mobbs as group CEO. New CEO is Steve Gray. Gray’s previous roles include healthcare services director at LloydsPharmacy, COO of its parent company Celesio, and group international healthcare director for AS Watson, the parent company of Superdrug.
Midmark Corporation
Ohio    
$390M
October 2015  
Midmark announced John Baumann - currently chair of its board of directors - has been appointed president and CEO. Current president and CEO, Dr. Anne Eiting Klamar, will become chair of the board.
Tufts Associated Health Plans  
Massachusetts
$156.5 M
October 2015  
Tufts Associated Health Plans announced that after a nearly 16-year career at the company, including 10 as CEO, Jim Roosevelt has announced his intention to step down as CEO, effective January 1, 2016. Current Tufts Health Plan President and Chief Operating Officer Tom Croswell will succeed Roosevelt as CEO.
Vision Eye Institute
Victoria
$86.9M
September 2015
Vision Eye Institute appointed Mr. Justin Walter as Managing Director & CEO. Mr. Walter will commence this role in December 2015. Mr. Walter is currently the General Manager, Health and Aged Care Sector for Spotless Group.
Vectura Group
Wiltshire
$86.2M
September 2015
Vectura Group plc appointed James Ward-Lilley as CEO and Executive Director has been confirmed with effect from the close of the General Meeting held on September 24, 2015.
Retire Australia Holdings Queensland
$67.7M
September 2015
The Board of RetireAustralia appointed Alison Quinn as the new CEO commencing in early 2016. Alison joins RetireAustralia from Aveo Limited where she was Executive General Manager Retirements, responsible for strategic and operational management of Aveo's Retirement Division.
Xenoport
California
$53.8M
October 2015
Vincent J. Angotti, EVP and COO, who has spearheaded the commercialization of HORIZANT, has been named CEO and has joined XenoPort’s Board of Directors.
CMC Biologics
Denmark         
$52.2M
October 2015  
CMC Biologics  announced the promotion of Gustavo Mahler, to be effective January 1, 2016, to serve as its CEO. Gustavo has more that 20 years of executive management experience in biologics manufacturing and development. Gustavo joined the company as head of the Seattle facility in 2008.
OmniSYS
Texas
$44.7M
September 2015
OmniSYS announced that John G. King is joining the company as CEO, effective September 21, 2015. King, who previously served as President of Standard Register's healthcare business, replaces interim CEO Andy Kieffer, who will continue to serve on the company board of directors.
Groupe Christie         
Quebec           
$32.5M            
October 2015  
Christie Innomed appointed Mr. Martin Roy as its new President and CEO.
AmeriHealth Administrators
Pennsylvania
$24.2M
September 2015
AmeriHealth Administrators announced that Michael Sullivan has been appointed president and CEO. Sullivan succeeds Richard Neeson.
Collagen Matrix
New Jersey
$11.5M
September 2015
Collagen Matrix announced an addition to its management team by naming Bart J. Doedens, former President of Biomet 3i, as its new CEO, effective immediately.
Cardica 
California
$2.99M
October 2015
Cardica appointed Julian Nikolchev as president, CEO and a member of the Cardica board of directors, effective from October 15, 2015. Mr. Nikolchev succeeds Bernard A. Hausen, M.D., Ph.D., who cofounded Cardica and served as president and CEO since 2000 and who announced that he was stepping down from his positions in August 2015.
Imaging Dynamics
Alberta
$2.03M            
October 2015  
Imaging Dynamics Company  announced that the Board of Directors has appointed Mr. Yucheng Zhou, the current Chairman of the Board of IDC, as CEO of the Company.
Nutranomics 
Utah
$1.8M
October 2015
On September 29, 2015, Michael Doron resigned from all officer positions and as a director of Nutranomics, and Edward J. Eyring, II, M.D., was appointed as CEO, CFO, and Secretary of the company.
CannLabs
Colorado         
$1.72M            
October 2015  
The Board of Directors of CannLabs announced that Vice Chairman Mark Mirken has rejoined the company as CEO. He has also been elected Chairman of the Board of Directors, replacing Mark Rogers who has stepped down from the Board of Directors. Mr. Mirken, served as CEO of CannLabs until earlier this year. In April, Mirken assumed a consulting role in order to focus on strategic partnerships and new business development as well as serving as Vice Chairman of the CannLabs board.
Albireo AB
Västra Götaland County
$0.356M
September 2015
Albireo Limited announced that Ron Cooper has joined the company as President and CEO. Mr. Cooper is a global biopharmaceutical leader with a track record of growing businesses, brands and organizations in the U.S. and Europe.  He joins Albireo from Bristol-Myers Squibb (BMS), where he was President of Europe.
Fate Therapeutics
California         
$0.329M          
October 2015  
Fate Therapeutics announced that Scott Wolchko will succeed Christian Weyer, M.D., M.A.S., as President and CEO following Dr. Weyer's resignation effective November 30, 2015.
Q Therapeutics
Utah
$0.178M
September 2015
Effective September 8, 2015, Deborah Eppstein resigned as President and CEO of Q Therapeutics.
Cellnovo Limited
West Glamorgan          $0.151 M
October 2015  
Cellnovo appointed Sophie Baratte as its CEO effective October 1, 2015. She has a distinguished career in healthcare having held senior positions at Johnson & Johnson, Sorin, CIT and Lifecell.
Cocrystal Pharma
Washington
$0.062M
September 2015
Cocrystal Pharma announced that its Board of Directors has appointed board member Jeffrey Meckler to the position of CEO, effective October 1, 2015.
Kips Bay Medical
Minnesota
$0.051M
September 2015
On September 22, 2015, the Board appointed Scott Kellen, the company’s COO and CFO, as CEO of the company in addition to his current positions with the company and elected Mr. Kellen as a director of the company, to be effective immediately.
The Medical Center of Aurora
Colorado
NA
October 2015
HCA-HealthONE appointed Dan Miller as President and CEO of The Medical Center of Aurora (TMCS). Miller takes over in this leadership role on October 5, 2015. Miller replaces Richard Hammett, who left TMCA in August after being named CEO at Swedish Medical Center.
Tokalas
California
NA
October 2015
Tokalas appointed James B. Breitmeyer, M.D., Ph.D. to the position of President & CEO and Board member of the company.
Biscayne Pharmaceuticals
Florida
NA
October 2015
Biscayne Pharmaceuticals announced that it has merged with Insero Health. Stephen Collins, MD, PhD, formerly CEO of Insero Health, has become President and CEO of Biscayne Pharmaceuticals.
Connecticut Childrens Medical Center
Connecticut
NA
October 2015
Connecticut Children's Medical Center has hired James E. Shmerling as its next president and CEO to succeed Martin Gavin, who is retiring.
Floyd Memorial Hospital and Health Services
Indiana
NA
October 2015
Floyd Memorial Hospital and Health Services has named Dr. Daniel J. Eichenberger new CEO. He had been serving as interim CEO since March. He was made the hospital's permanent CEO in a unanimous board of trustees vote.
Access Integrated Healthcare
California
NA
September 2015
Access Integrated Healthcare (AIH) announced that its board of directors has named Manel Sweetmore as CEO. Sweetmore previously served as AIH's Chief Financial Offer and COO.
Agendia N.V.
Noord-Holland
NA
September 2015
Agendia N.V., appointed veteran diagnostics industry leader Mark R. Straley as CEO. He succeeds Jan Egberts, M.D., who took on the position of CEO last October on an interim basis.
The Brooklyn Hospital Center
New York
NA
September 2015
The Brooklyn Hospital Center’s Board of Trustees appointed Gary G. Terrinoni as the hospital’s new President and CEO. Mr. Terrinoni is presently EVP of Administration (COO) and CFO of Kennedy Health System.
Palmaz Scientific
Texas
NA
September 2015
Palmaz Scientific announced that Dr. Philippe Henri Marco has been named as President and CEO of the company. Dr. Marco replaces former CEO Steven Solomon who resigned to pursue other opportunities.
PROMETHERA Biosciences
Walloon Brabant
NA
September 2015
Promethera Biosciences has appointed Dr. John Tchelingerian as its new CEO. John Tchelingerian joined the company as Chairman of the Board on 8 December, 2014, and has acted as its interim CEO since 23 January, 2015.
Brainstorm Cell Therapeutics 
New Jersey
NA
September 2015
BrainStorm Cell Therapeutics appointed Mr. Chaim Lebovits, has been serving as the Company's President since July 2007, as CEO. Mr. Lebovits succeeds Dr. Tony Fiorino, is anticipated to remain with the Company in an executive scientific role to be announced shortly.
MedGen
New York
NA
September 2015
Medgen announced that it has completed the acquisition of Alternaturals. The company has also undergone some internal changes. Former Medgen CEO Brandon Dean has stepped down pursue other opportunities, while Mr. Matthew Briggs, the CEO of Alternaturals has taken the helm as Medgen's new CEO. 
Bicycle Therapeutics
Cambridgeshire
NA
September 2015
Bicycle Therapeutics Limited appointed Kevin Lee, Ph.D., as CEO. Dr. Lee brings more than 20 years of experience in drug discovery and development leadership, most recently from Pfizer, spanning the pharmaceutical and biotechnology industries as well as academia.
AxisPoint Health
Colorado
NA
September 2015
AxisPoint Health announced that Dr. Ron Geraty is joining the company as CEO. Dr. Geraty brings expertise in the population health and care management space to AxisPoint Health, having founded, led, and transformed multiple healthcare companies
Sun BioPharma
Minnesota
NA
September 2015
Sun BioPharma announced that David B. Kaysen, has been appointed President and CEO as well as a member of the company's Board of directors effective immediately.
Joslin Diabetes Center
Massachusetts
NA
September 2015
Joslin Diabetes Center announced a new president and CEO, a week after seeking and getting the resignation its previous CEO of five years. Dr. Peter Amenta has been appointed to the position, effective Oct. 5, 2015.
Xcede Technologies
Minnesota
NA
September 2015
Dynasil Corporation of America appointed Linda Zuckerman, Ph.D. as CEO of Xcede Technologies, Dynasil's majority owned subsidiary.
Molecular Response
California
NA
September 2015
Molecular Response appointed Brett M. Hall, Ph.D. as CEO. In this new role, Dr. Hall will spearhead the repositioning of Molecular Response into a drug development company, Molecular Response Therapeutics, whose primary focus will be to identify and develop novel agents that disrupt tumor cell interactions with permissive host tumor microenvironments.
United Lincolnshire Hospitals NHS Trust
Lincolnshire
NA
September 2015
Jan Sobieraj has been appointed new CEO of United Lincolnshire Hospitals NHS Trust. This appointment follows the retirement of Jane Lewington in August.
Trinity Home Health Services
Michigan
NA
September 2015
Trinity Health announced that Erin M. Denholm will join its leadership team in October 2015 as the new president and CEO of Trinity Home Health Services. In her role, Denholm will be accountable for the overall operations, quality and financial performance of THHS.
Access Homehealth
New Zealand
NA
September 2015
Green Cross Health appointed Simon Lipscombe as the CEO of Access Homehealth effective 28 October 2015. Simon has spent the last 7 years with Spotless in New Zealand, most recently as the Country General Manager.
Skookum Safety Solutions
Costa Rica
NA
October 2015
The company announced that Yaojun Liu was appointed as CEO, Chief Financial Officer and Chairman. Mr. Liu has been the Vice President of Kirin International Holdings
AVAX Technologies 
Pennsylvania
NA
October 2015
AVAX Technologies  announced the expansion of its executive team with the appointment of Adele Sommerfeld as CEO.
Faraday Pharmaceuticals
Washington
NA
October 2015
Faraday Pharmaceuticals appointed Stephen Hill, M.D., as CEO. He served as CEO and president of Targacept.
Walker Regional Medical Center
Alabama
NA
October 2015
The newly-formed joint venture Walker Baptist Medical Center, between Tenet Healthcare and Baptist Health System announced that John Langlois has been hired to the position since serving as interim CEO in March. Langlois will replace Bob Phllips, who became the CEO of Shelby Baptist Medical Center earlier 2015.
Checkpoint Therapeutics
New York
NA
October 2015
Checkpoint Therapeutics announced that Mr. James F. Oliviero, III, has been appointed President and CEO. Mr. Oliviero will also be appointed to Checkpoint's Board of Directors.
Q BioMed 
New York
NA
October 2015
Q BioMed on October 8, 2015 announced that Mr. Denis Corin, the company's current President, was appointed to the positions of CEO and Chairman of the Board of Directors.
Emory Saint Joseph's Hospital of Atlanta
Georgia
NA
October 2015
Heather Dexter will take the reins October 23, 2015, as the new CEO of Emory Saint Joseph's Hospital.
O'Connor Hospital
California
NA
October 2015
Robert Minkin, FACHE, has been appointed as President & CEO of O'Connor Hospital. He succeeds Sister Margaret Keaveney, DC, who will continue as President & CEO at Saint Louise Regional Hospital in Gilroy until a new CEO is selected to replace her.
Zest Health
Illinois
NA
October 2015
Zest Health has named experienced health technology executive and entrepreneur Anna Mond Johnson as CEO. With more than 20 years of experience, Mond Johnson is a nationally recognized leader in healthcare consumerism and has built her career managing innovative healthcare technology companies.
Read 2358 times Last modified on Wednesday, 10 June 2020 14:30
Dora Vell

Dora Vell is the Managing Partner of Vell Executive Search, a boutique executive search firm in Boston focused on recruiting technology executives and board members. Vell has successfully completed numerous board member and C-level executive searches, including CEOs, COOs, CIOs, and Vice Presidents - at both public and private companies.

Prior to founding the firm in 2005, Vell was a Partner at Heidrick & Struggles' Technology practice for seven years.  Before her career in executive search, she worked at IBM for 11 years, managing software engineering organizations of 100 people and software sales organizations with revenues of $150 million. She has also served as an executive assistant to the CEO of IBM Canada for one year.

Vell holds seven worldwide software patents. She has published several Business of Leadership reports on governance and leadership and has been quoted in numerous articles including The Wall Street Journal, Forbes, Business Week, Fortune, Agenda Week, MSNBC, Mass High Tech, the OPUS for the World Economic Forum, Boston Business Journal, The Globe & Mail, CIO Magazine, and IEEE. She also has been a featured speaker on leadership at numerous conferences and at Columbia University's MBA program.

Vell is a member of the National Association of Corporate Directors (NACD), the Boston CEO Roundtable. She has served on the boards of Framingham State, Entrepreneur's Organization, Goodwill, Mary Centre for developmentally handicapped adults, garage.ca, and RBC Capital Partners.

She has received an MBA from the University of Toronto, a Master in Computer Science from the University of Waterloo, and a Bachelor in Computer Science from Carleton. She has also completed the MIT Entrepreneurial Master’s program.

www.vell.com

Leave a comment

Subscribe to Vell Leadership Insights

Track leadership moves and stay up to date with current trends